Glenmark Pharmaceuticals is expecting to achieve a significant growth in next three to four years on the back of strong pipeline of speciality and innovative products. Speciality and innovative products will comprise 30 per cent of its revenues by 2025.
The next few years will see consistent revenues and profitability without the need for inorganic growth through acquisitions. Over the last few years the company has invested significantly to mark the step-wise transition from generics to an innovation-driven organisation.
